Allspring Global Investments Holdings LLC Sells 130,872 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Allspring Global Investments Holdings LLC cut its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 35.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 237,860 shares of the biotechnology company’s stock after selling 130,872 shares during the period. Allspring Global Investments Holdings LLC owned about 0.31% of Axon Enterprise worth $95,049,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Blue Trust Inc. increased its holdings in Axon Enterprise by 987.5% in the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 79 shares during the period. Trivant Custom Portfolio Group LLC acquired a new position in Axon Enterprise in the first quarter worth about $31,000. Quent Capital LLC raised its position in Axon Enterprise by 1,875.0% in the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 75 shares in the last quarter. First PREMIER Bank bought a new position in Axon Enterprise during the first quarter worth about $33,000. Finally, Asset Dedication LLC acquired a new stake in Axon Enterprise during the second quarter valued at approximately $47,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on AXON shares. Jefferies Financial Group started coverage on Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 target price for the company. Barclays increased their price objective on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Needham & Company LLC restated a “buy” rating and issued a $400.00 target price on shares of Axon Enterprise in a research note on Wednesday, August 7th. Bank of America started coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $380.00 target price for the company. Finally, Robert W. Baird boosted their price target on shares of Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $365.38.

Axon Enterprise Stock Up 0.8 %

Shares of NASDAQ:AXON opened at $438.05 on Monday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The stock has a market cap of $33.10 billion, a price-to-earnings ratio of 115.58, a P/E/G ratio of 11.74 and a beta of 0.94. The company has a 50 day moving average of $388.71 and a 200-day moving average of $331.79. Axon Enterprise, Inc. has a one year low of $199.29 and a one year high of $440.89.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter in the previous year, the company posted $0.80 EPS. The business’s revenue for the quarter was up 34.5% compared to the same quarter last year. On average, sell-side analysts forecast that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.

Insider Buying and Selling at Axon Enterprise

In other news, Director Michael Garnreiter sold 1,000 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total transaction of $437,980.00. Following the completion of the transaction, the director now directly owns 26,259 shares in the company, valued at approximately $11,500,916.82. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Patrick W. Smith sold 80,300 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the sale, the chief executive officer now owns 3,015,366 shares of the company’s stock, valued at approximately $1,121,052,771.48. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total value of $437,980.00. Following the transaction, the director now owns 26,259 shares in the company, valued at approximately $11,500,916.82. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 371,172 shares of company stock valued at $137,000,162. 6.10% of the stock is currently owned by company insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.